Calling on Centers for Medicare & Medicaid Services to Curb Below-Cost Reimbursement to Specialty Pharmacies by Pharmaceutical Benefit Managers, to Clarify Medicare Definitions, & Promote Accurate & Responsible Reimbursement
Direct & Indirect Remuneration (DIR) fees erode access to vital clinical services & breakthrough drugs for the most vulnerable Americans, increasing costs across the board & negatively impacting seniors & their caregivers, pharmacies, & taxpayers that fund Medicare
Last week, Frier Levitt, LLC; and the National Association of Specialty Pharmacy (NASP) published a white paper describing the advent and negative consequences of Direct and Indirect Remuneration (DIR) fees. America’s seniors need the Centers for Medicare and Medicaid Services (CMS) to take immediate action to stop Pharmaceutical Benefits Managers (PBMs) from levying inappropriate, unreasonable and unsustainable DIR fees on specialty pharmacies.
